Tag: Prescription Drugs
FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis
Twice-daily oral tablet marks first approval of idiopathic pulmonary fibrosis in more than 10 years
Tramadol May Have Slight Effect on Reducing Chronic Pain
Evidence seen, however, for harmful effects from serious adverse events and several nonserious adverse events
ACS: 2020 to 2024 Saw Jump in Use of GLP-1 Receptor Agonists Before Metabolic,...
Even higher use seen in patients without type 2 diabetes
Sotatercept Reduces Risk for Clinical Worsening in Adults With Recently Diagnosed PAH
Benefit with sotatercept seen among adults with pulmonary arterial hypertension diagnosed less than a year earlier
FDA Approves Zoryve for Atopic Dermatitis in Young Children
The once-daily cream can be used anywhere on the body and offers an alternative to steroids in children ages 2 to 5 years
Budesonide-Formoterol More Effective Than Salbutamol for Preventing Asthma Attacks in Children
Similar safety profile seen in children with mild asthma aged 5 to 15 years
Rate of Gabapentin Prescribing Increasing Since 2010
Rate of dispensing almost doubled for both number of prescriptions and people from 2010 to 2016, followed by slower increase
Ocrelizumab Provides Superior Relapse Control in Multiple Sclerosis
Control of relapses improved compared with fingolimod, natalizumab, and alemtuzumab
FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
40 percent of children achieved complete skin clearance at week 16 with Tremfya versus placebo
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
Risk reductions stronger in those with psoriasis versus those with obesity or type 2 diabetes without psoriasis
